AVITA Medical's Spray-On Skin Cells device rapidly processes a patient's own skin to treat large dermatological injuries. The company's sales growth is expected to accelerate in 2024 due to the ...
Please provide your email address to receive an email when new articles are posted on . Melanocyte-keratinocyte transplant procedures are rare in the U.S. due to a need for specialized equipment. The ...
AVITA Medical, a regenerative medicine company, is pioneering the RECELL System - a patient-specific skin cell solution aimed at revolutionizing skin restoration. The company saw a 40% increase in ...
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, ...
Please provide your email address to receive an email when new articles are posted on . Melanocyte keratinocyte transplantation can yield significant repigmentation ranging from 70% to 100%. The ...
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
VALENCIA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted ...
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases ...
On August 7, 2025, AVITA released its second quarter 2025 financial results, revealing “a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.” The Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results